Amyloid A Amyloidosis After Renal Transplantation: An Important Cause of Mortality.
Adult
Allografts
/ immunology
Amyloidosis
/ immunology
Biopsy
Familial Mediterranean Fever
/ complications
Female
Follow-Up Studies
Graft Rejection
/ immunology
Graft Survival
/ immunology
Humans
Kaplan-Meier Estimate
Kidney
/ immunology
Kidney Failure, Chronic
/ immunology
Kidney Transplantation
/ adverse effects
Male
Middle Aged
Recurrence
Retrospective Studies
Serum Amyloid A Protein
/ immunology
Survival Rate
Treatment Outcome
Young Adult
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
21
10
2020
Statut:
ppublish
Résumé
There are limited data on the outcome of transplant recipients with familial Mediterranean fever (FMF)-associated AA amyloidosis. The aim of the present study is to evaluate demographic, clinical, laboratory, and prognostic characteristics and outcome measures of these patients. Eighty-one renal transplant recipients with FMF-associated AA amyloidosis (group 1) and propensity score-matched transplant recipients (group 2, n = 81) with nonamyloidosis etiologies were evaluated in this retrospective, multicenter study. Recurrence of AA amyloidosis was diagnosed in 21 patients (group 1a), and their features were compared with 21 propensity score-matched recipients with FMF amyloidosis with no laboratory signs of recurrence (group 1b). The risk of overall allograft loss was higher in group 1 compared with group 2 (25 [30.9%] versus 12 [14.8%]; P = 0.015 [hazard ratio, 2.083; 95% confidence interval, 1.126-3.856]). Patients in group 1 were characterized by an increased risk of mortality compared with group 2 (11 [13.6%] versus 0%; P = 0.001 [hazard ratio, 1.136; 95% confidence interval, 1.058-1.207]). Kaplan-Meier analysis revealed that 5- and 10-year patient survival rates in group 1 (92.5% and 70.4%) were significantly lower than in group 2 (100% and 100%; P = 0.026 and P = 0.023, respectively). Although not reaching significance, overall, 5- and 10-year graft survival rates (57.1%, 94.7%, and 53.8%, respectively) in group 1a were worse than in group 1b (76.2%, 95%, and 77.8%, respectively; P = 0.19, P = 0.95, and P = 0.27, respectively). AA amyloidosis is associated with higher risk of mortality after kidney transplantation. Inflammatory indicators should be monitored closely, and persistent high levels of acute-phase reactants should raise concerns about amyloid recurrence in allograft.
Sections du résumé
BACKGROUND
There are limited data on the outcome of transplant recipients with familial Mediterranean fever (FMF)-associated AA amyloidosis. The aim of the present study is to evaluate demographic, clinical, laboratory, and prognostic characteristics and outcome measures of these patients.
METHODS
Eighty-one renal transplant recipients with FMF-associated AA amyloidosis (group 1) and propensity score-matched transplant recipients (group 2, n = 81) with nonamyloidosis etiologies were evaluated in this retrospective, multicenter study. Recurrence of AA amyloidosis was diagnosed in 21 patients (group 1a), and their features were compared with 21 propensity score-matched recipients with FMF amyloidosis with no laboratory signs of recurrence (group 1b).
RESULTS
The risk of overall allograft loss was higher in group 1 compared with group 2 (25 [30.9%] versus 12 [14.8%]; P = 0.015 [hazard ratio, 2.083; 95% confidence interval, 1.126-3.856]). Patients in group 1 were characterized by an increased risk of mortality compared with group 2 (11 [13.6%] versus 0%; P = 0.001 [hazard ratio, 1.136; 95% confidence interval, 1.058-1.207]). Kaplan-Meier analysis revealed that 5- and 10-year patient survival rates in group 1 (92.5% and 70.4%) were significantly lower than in group 2 (100% and 100%; P = 0.026 and P = 0.023, respectively). Although not reaching significance, overall, 5- and 10-year graft survival rates (57.1%, 94.7%, and 53.8%, respectively) in group 1a were worse than in group 1b (76.2%, 95%, and 77.8%, respectively; P = 0.19, P = 0.95, and P = 0.27, respectively).
CONCLUSIONS
AA amyloidosis is associated with higher risk of mortality after kidney transplantation. Inflammatory indicators should be monitored closely, and persistent high levels of acute-phase reactants should raise concerns about amyloid recurrence in allograft.
Identifiants
pubmed: 32732850
doi: 10.1097/TP.0000000000003043
pii: 00007890-202008000-00032
doi:
Substances chimiques
Serum Amyloid A Protein
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1703-1711Références
Ozen S. Renal amyloidosis in familial Mediterranean fever. Kidney Int. 2004; 65:1118–1127
Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum. 2009; 61:1447–1453
van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med. 2005; 5:87–98
Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007; 356:2361–2371
Abedi AS, Nakhjavani JM, Etemadi J. Long-term outcome of renal transplantation in patients with familial Mediterranean fever amyloidosis: a single-center experience. Transplant Proc. 2013; 45:3502–3504
Sherif AM, Refaie AF, Sobh MA, et al. Long-term outcome of live donor kidney transplantation for renal amyloidosis. Am J Kidney Dis. 2003; 42:370–375
Kofman T, Grimbert P, Canouï-Poitrine F, et al. Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study. Am J Transplant. 2011; 11:2423–2431
Green H, Lichtenberg S, Rahamimov R, et al. Familial Mediterranean fever is associated with increased mortality after kidney transplantation-A 19 years’ single center experience. Transplantation. 2017; 101:2621–2626
Sawinski D, Lim MA, Cohen JB, et al. Patient and kidney allograft survival in recipients with end-stage renal disease from amyloidosis. Transplantation. 2018; 102:300–309
Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014; 33:1242–1258
Haas M, Sis B, Racusen LC, et al.; Banff Meeting Report Writing CommitteeBanff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014; 14:272–283
Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55:713–723
R Core Team (2013)R: A Language and Environment for Statistical Computing. The R Foundation.2018Available at http://www.R-project.org/. Accessed January 14, 2019
Caliendo M, Kopeinig S. Some practical guidance for the implementation of propensity score matching. J Econ Surv. 2008; 22:31–72
Tang W, McDonald SP, Hawley CM, et al. End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrol Dial Transplant. 2013; 28:455–461
Türkmen A, Yildiz A, Erkoç R, et al. Transplantation in renal amyloidosis. Clin Transplant. 1998; 12:375–378
Sever MS, Turkmen A, Sahin S, et al. Renal transplantation in amyloidosis secondary to familial Mediterranean fever. Transplant Proc. 2001; 33:3392–3393
Gursu M, Yelken B, Caliskan Y, et al. Outcome of patients with amyloidosis after renal transplantation: a single-center experience. Int J Artif Organs. 2012; 35:444–449
Sahutoglu T, Atay K, Caliskan Y, et al. Comparative analysis of outcomes of kidney transplantation in patients with AA amyloidosis and chronic glomerulonephritis. Transplant Proc. 2016; 48:2011–2016
Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001; 358:24–29
Gertz MA, Skinner M, Sipe JD, et al. Serum amyloid A protein and C-reactive protein in systemic amyloidosis. Clin Exp Rheumatol. 1985; 3:317–320
Reinhart WH, Nagy C. Albumin affects erythrocyte aggregation and sedimentation. Eur J Clin Invest. 1995; 25:523–528
Livneh A, Zemer D, Siegal B, et al. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron. 1992; 60:418–422
Speeg KV, Maldonado AL, Liaci J, et al. Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo. J Pharmacol Exp Ther. 1992; 261:50–55
van der Hilst JCh, Moutschen M, Messiaen PE, et al. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016; 10:75–80
Özçakar ZB, Keven K, Çakar N, et al. Transplantation within the era of anti-IL-1 therapy: case series of five patients with familial Mediterranean fever-related amyloidosis. Transpl Int. 2018; 31:1181–1184